Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1978 Feb;19(2):108-13.
doi: 10.1136/gut.19.2.108.

Escherichia coli antibodies in patients with inflammatory bowel disease

Escherichia coli antibodies in patients with inflammatory bowel disease

S Tabaqchali et al. Gut. 1978 Feb.

Abstract

Sera from 30 patients with inflammatory bowel disease (IBD) (16 with Crohn's disease (CD) and 14 with ulcerative colitis (UC) were assayed for the presence of antibodies against 159 Escherichia coli O-antigens and compared with sera from 16 matched control subjects. The majority of patients with IBD had agglutinating antibodies to a higher number of Escherichia coli O-antigens and in higher titres than the control group. The number of positive agglutinins was O-33 mean 13.8 in CD, O-26 mean 7.9 for UC, and O-7 mean 1.5 in controls. Eight patients with IBD and arthropathy had antibodies to fewer O-antigens (O-7 mean 3.2). The antibodies were in the IgG and IgM, in titres corresponding to original values. No specific O-serotypes were associated with IBD. Common serotypes, R-plasmid carrying serotypes, and those associated with shigella-like adult diarrhoea were detected. O14 was detected only in five patients and O119 in none. There was no correlation between the number of Escherichia coli agglutinins and the site and severity of the disease or type of therapy. It is suggested that the presence of the high numbers of Escherichia coli antibodies is secondary to the disease process and is unlikely to be causally involved in the pathogenesis of the disease, but may play a role in the perpetuation of the disease and in the extraintestinal complications.

PubMed Disclaimer

References

    1. Proc Soc Exp Biol Med. 1967 Jul;125(3):975-80 - PubMed
    1. J Exp Med. 1959 Nov 1;110:657-74 - PubMed
    1. J Bacteriol. 1963 Mar;85:541-8 - PubMed
    1. Pediatrics. 1955 Dec;16(6):801-8 - PubMed
    1. AMA Arch Intern Med. 1958 Jul;102(1):134-48 - PubMed

LinkOut - more resources